InvestorsHub Logo
Followers 32
Posts 2552
Boards Moderated 0
Alias Born 07/16/2006

Re: DewDiligence post# 2620

Thursday, 12/14/2006 10:03:45 PM

Thursday, December 14, 2006 10:03:45 PM

Post# of 51989
Hank Mansbach will be the SVP for Drug Development at Valeant Pharmaceuticals. A very very different kind of company from Cortex--everything is inlicensed, though they do some drug development work in order to get a drug ready for commercialization--their main project at present is the anticonvulsant Retigabine. Valeant-who subscribes to NI and converses with me on occasion, is looking to become more involved in the neurology area.

Difference of scale: Valeant employs over 3000 people--and last year had product sales of $750 million. I think it's safe to say that Dr. Mansbach will be compensated at a considerably higher level there than at Cortex.

NeuroInvestment
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News